STOCK TITAN

XOMA Royalty Declares Quarterly Preferred Stock Dividends

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends

XOMA Royalty Corporation (NASDAQ: XOMA) has declared quarterly cash dividends for its preferred stockholders. The company will distribute dividends to two classes of preferred shares:

- Holders of 8.625% Series A Preferred Stock (NASDAQ: XOMAP) will receive $0.53906 per share
- Holders of 8.375% Series B Preferred Stock (NASDAQ: XOMAO) will receive $0.52344 per depositary share

Both dividends are scheduled for payment on October 15, 2025, to shareholders of record as of October 3, 2025.

Loading...
Loading translation...

Positive

  • Consistent dividend payments demonstrating financial stability
  • Maintaining preferred stock dividend obligations

Negative

  • None.

News Market Reaction 1 Alert

+1.25% News Effect

On the day this news was published, XOMA gained 1.25%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:  

Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.  

Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.  

The preferred dividends will be paid on or about October 15, 2025, to respective holders of record at the close of business on October 3, 2025.  

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.   XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the sellers receive non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.  

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.  

As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet).  All other assets in the milestone and royalty portfolio are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of the investigational compounds will become commercially available.  

Investor Contact             
Juliane Snowden            
XOMA Royalty Corporation        
+1-646-438-9754            
juilane.snowden@xoma.com
XOMA Royalty Media Contact
Kathy Vincent
KV Consulting & Management
kathy@kathyvincent.com

FAQ

What is the dividend amount for XOMA Series A Preferred Stock (XOMAP) for Q4 2025?

XOMA's Series A Preferred Stock (XOMAP) holders will receive a cash dividend of $0.53906 per share for Q4 2025.

When is the payment date for XOMA's preferred stock dividends?

XOMA will pay the preferred stock dividends on October 15, 2025 to shareholders of record as of October 3, 2025.

What is the dividend yield for XOMA Series B Preferred Stock (XOMAO)?

XOMA Series B Preferred Stock has an 8.375% dividend yield, with holders receiving $0.52344 per depositary share.

What is the record date for XOMA's Q4 2025 preferred dividends?

The record date for XOMA's preferred stock dividends is October 3, 2025.
XOMA Royalty Corporation

NASDAQ:XOMA

XOMA Rankings

XOMA Latest News

XOMA Latest SEC Filings

XOMA Stock Data

370.50M
12.16M
0.94%
68.02%
2.19%
Biotechnology
Pharmaceutical Preparations
Link
United States
EMERYVILLE